Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

BACKGROUND: Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%...

Descripción completa

Detalles Bibliográficos
Autores principales: Hájek, Roman, Bryce, Richard, Ro, Sunhee, Klencke, Barbara, Ludwig, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489882/
https://www.ncbi.nlm.nih.gov/pubmed/22992303
http://dx.doi.org/10.1186/1471-2407-12-415

Ejemplares similares

Ejemplares similares